Typhoid conjugate vaccine implementation in India: A review of supportive evidence
Background: Typhoid conjugate vaccines are available in the private market in India and are also recommended by the National Technical Advisory Group on Immunisation (NTAGI) for inclusion in India’s Universal Immunisation Programme in 2022 to control and prevent typhoid fever. Our study aims to synt...
Saved in:
| Main Authors: | Vijayalaxmi V. Mogasale, Anish Sinha, Jacob John, Habib Hasan Farooqui, Arindam Ray, Tracey Chantler, Vittal Mogasale, Bhim Gopal Dhoubhadel, W John Edmunds, Andrew Clark, Kaja Abbas |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2024-12-01
|
| Series: | Vaccine: X |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2590136224001414 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
One-month evaluation of safety and immunogenicity of a Vi-DT typhoid conjugate vaccine (Bio-TCV®) in Indonesian subjects 6 months to 45 years: A phase III randomized clinical trial
by: Bernie Endyarni Medise, et al.
Published: (2025-08-01) -
Single and two-dose typhoid conjugate vaccine safety and immunogenicity in HIV-exposed uninfected and HIV-unexposed uninfected Malawian children
by: Nginache Nampota-Nkomba, et al.
Published: (2024-12-01) -
Surgical Complications of Typhoid Fever: First National Typhoid Conference in Niamey, Niger [version 1; peer review: awaiting peer review]
by: Ide Kadi, et al.
Published: (2025-05-01) -
Comparative immune response of Typbar TCV® (typhoid conjugate vaccine) in extremes of age: An Indian experience
by: Krishna Mohan Vadrevu, et al.
Published: (2025-12-01) -
A multi-centre, single arm, Phase 3 study to assess the safety and reactogenicity of biological Es Vi-capsular polysaccharide-CRM197 conjugate typhoid vaccine in ≥6 months old infants to ≤45 years old adults.
by: Subhash Thuluva, et al.
Published: (2025-08-01)